Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
3960 results about "Virus resistance" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Macrocyclic hepatitis C serine protease inhibitors
The present invention relates to compounds of Formula I, II or Ill, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:
wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Owner:ENANTA PHARM INC
Heterocyclic antiviral compounds
Compounds having the formula I wherein A, m and R1 are herein defined are Hepatitis C virus polymerase inhibitors. Also disclosed are compositions and methods for treating diseases mediated by HCV and for inhibiting hepatitis replication. Also disclosed are processes for making the compounds and synthetic intermediates used in the process
Owner:ROCHE PALO ALTO LLC
Effecting virus resistance in plants through the use of negative strand RNAs
InactiveUS6617496B1Sugar derivativesOther foreign material introduction processesNegative strandPlant cell
A strategy for effecting virus resistance in plants causes the transcription in the plant cells of negative RNA strands which are substantially complementary to a target RNA strand. The target RNA strand can be an mRNA transcript created in gene expression, a viral RNA, or other RNA present in the plant cells. The negative RNA strand is complementary to at least a portion of the target RNA strand to inhibit its activity in vivo.
Owner:AGRACETUS MIDDLETON WISCONSIN A GENERAL PARTNERSHIP OF NEW YORK +1
Homogeneous preparations of IL-28 and IL-29
ActiveUS7157559B2Improve expression levelIncrease productionPeptide/protein ingredientsAntipyreticMutated proteinPolynucleotide
Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
Owner:ZYMOGENETICS INC
Antiviral phosphoramidates
The invention provides novel nucleoside compounds of formula I wherein R1, R2a, R2b, R3, R4, R5, R6, R8a, R9 and R10 are as defined herein which are useful for the treatment of Hepatitis C Virus (HCV) mediated diseases. The invention further provides methods for treatment or prophylaxis of HCV mediated diseases with compounds of formula I and pharmaceutical compositions comprising these compounds,
Owner:RIBOSCI
High-neutralizing-activity anti-SARS-CoV-2 fully-humanized monoclonal antibody and application thereof
ActiveCN111303280AGood neutralizing effectReduced responseImmunoglobulins against virusesAntiviralsDiseaseAntiendomysial antibodies
The invention discloses an anti-SARS-CoV-2 fully-humanized monoclonal antibody against SARS-CoV-2. The antibody is obtained by screening through a flow sorting-single cell PCR technology, and has a unique CDR partition. The invention further discloses an application of the antibody in preparation of medicines for treating the 2019-coronavirus disease. The monoclonal antibody disclosed by the invention has efficient and specific anti-SARS-COV-2 activity, also has the characteristics of high expression, complete humanization and good stability, and is suitable for industrial production.
Owner:ACADEMY OF MILITARY MEDICAL SCI
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
InactiveUS7273885B2Inhibit HCV replicationReduce riskBiocidePeptide/protein ingredientsHepatitis c viralSerine Protease Inhibitors
The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
Owner:VERTEX PHARMA INC
Hepatitis c virus inhibitors
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:
which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.
Owner:ENANTA PHARM INC
Novel benzimidazole derivatives
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:
which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Owner:ENANTA PHARM INC
Heterocyclic antiviral compounds
Compounds having the formula I wherein A, m and R1 are herein defined are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for inhibiting hepatitis replication, processes for making the compounds and synthetic intermediates used in the process
Owner:ROCHE PALO ALTO LLC
Hepatitis c virus inhibitors
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.
Owner:ENANTA PHARM INC
Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
The present invention is directed to compounds, compositions and methods for treating or preventing cancer and viral infections, in particular, HIV, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV in human patients or other animal hosts. The compounds are certain 6-substituted purine monophosphates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1, HIV-2, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV.
Owner:EMORY UNIVERSITY
Linked dibenzimidazole antivirals
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:
which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Owner:ENANTA PHARM INC
Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates
ActiveUS7749983B2Improve bioactivityImprove bioavailabilityBiocideSugar derivativesMedical disorderPhosphate
The present invention relates to phosphonate, nucleoside phosphonate or nucleoside phosphate compounds, compositions containing them, processes for obtaining them, and their use in treating a variety of medical disorders, in particular viral infections, cancers and the like.
Owner:RGT UNIV OF CALIFORNIA +2
Multiple virus resistance in plants
The present invention provides gene targets, constructs and methods for the genetic control of plant disease caused by multiple plant viruses. The present invention relates to achieving a plant protective effect through the identification of target coding sequences and the use of recombinant DNA technologies for post-transcriptionally repressing or inhibiting expression of the target coding sequences of plant-parasitic viruses. Protein-expression based approaches may also be utilized to augment phenotype resistance. Thus, transcription of a single transgenic event comprising one or more plant expression cassettes can allow for broad spectrum resistance of a plant to multiple plant viral strains and species among the geminiviruses, tospoviruses, and potexviruses.
Owner:MONSANTO TECH LLC
Human Antibodies to Ebola Virus Glycoprotein
ActiveUS20160215040A1Inhibiting and neutralizing activityAvoid enteringImmunoglobulins against virusesAntiviralsViral glycoproteinAntigen Binding Fragment
The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to Ebola virus glycoproteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing Ebola virus activity, thus providing a means of treating or preventing Ebola virus infection in humans. In some embodiments, the invention provides for use of one or more antibodies that bind to the Ebola virus for preventing viral attachment and/or entry into host cells. The antibodies of the invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.
Owner:REGENERON PHARM INC
Hepatitis c virus inhibitors
ActiveUS20110189129A1Improve pharmacokineticsImproving the pharmacokinetics of drugsBiocidePeptide/protein ingredientsHepatitis c viralPharmaceutical drug
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof:
Q-G-A-L-B—W (I),
which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Owner:ENANTA PHARM INC
New [1,2,3]-thiobiazole derivative and its synthesis and use
The present invention provides one kind of 1, 2, 3-thiobiazole-5-formamide compounds and their synthesis process and pesticide bioactivity screening. The screening system includes the determination of tobacco mosaic disease resisting activity, tobacco mosaic disease virus resistance inducing activity, and pesticidal and fungus-inhibiting activity. The related compounds are 1, 2, 3-thiobiazole-5-formamide derivatives with the general expression as shown, and include 7 hetero cycle containing 1, 2, 3-thiobiazole-5-formamide derivatives, 2 benzene ring containing 1, 2, 3-thiobiazole-5-formamide derivatives, and 2 aliphatic radical containing 1, 2, 3-thiobiazole-5-formamide derivatives.![New [1,2,3]-thiobiazole derivative and its synthesis and use](https://images-eureka.patsnap.com/patent_img/bb62cff4-315a-4103-a7ad-a9e25aec5b9e/A2006100131850002C1.PNG "New [1,2,3]-thiobiazole derivative and its synthesis and use")
![New [1,2,3]-thiobiazole derivative and its synthesis and use](https://images-eureka.patsnap.com/patent_img/bb62cff4-315a-4103-a7ad-a9e25aec5b9e/A2006100131850002C2.PNG "New [1,2,3]-thiobiazole derivative and its synthesis and use")
![New [1,2,3]-thiobiazole derivative and its synthesis and use](https://images-eureka.patsnap.com/patent_img/bb62cff4-315a-4103-a7ad-a9e25aec5b9e/A2006100131850003C1.PNG "New [1,2,3]-thiobiazole derivative and its synthesis and use")
Owner:LIER CHEM CO LTD
Structure and use of 5' phosphate oligonucleotides
Oligonucleotides bearing free, uncapped 5′ phosphate group(s) are recognized by RIG-I, leading to the induction of type I IFN, IL-18 and IL-1β production. Bacterial RNA also induces type I IFN production. 5′ phosphate oligonucleotides and bacterial RNA can be used for inducing an anti-viral response or an anti-bacterial response, in particular, type I IFN and / or IL-18 and / or IL-1β production, in vitro and in vivo and for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, tumors, allergies, autoimmune diseases, immunodeficiencies and immunosuppression. Single-stranded 5′ triphosphate RNA can be used for inducing an anti-viral response, an anti-bacterial response, or an anti-tumor response, in particular, type I IFN and / or IL-18 and / or IL-1β production, in a target cell-specific manner.
Owner:UNIVERSITY OF BONN
Antisense antiviral compound and method for treating ssRNA viral infection
ActiveUS20060269911A1Promote absorptionSsRNA viruses positive-senseMicrobiological testing/measurementOligonucleotideAstroviridae
The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Flaviviridae, Picomoviridae, Caliciviridae, Togaviridae, Arteriviridae, Coronaviridae, Astroviridae and Hepeviridae families in the treatment of a viral infection. The antisense antiviral compounds are substantially uncharged morpholino oligonucleotides having a sequence of 1240 subunits, including at least 12 subunits having a targeting sequence that is complementary to a region associated with stem-loop secondary structure within the 5′-terminal end 40 bases of the positive-sense RNA strand of the virus.
Owner:AVI BIOPHARMA
Antiviral phosphoramidates
The invention provides novel nucleoside compounds of formula I wherein R1, R2a, R2b, R3, R4, R5 R6, R8a, R9 and R10 are as defined herein which are useful for the treatment of Hepatitis C Virus (HCV) mediated diseases. The invention further provides methods for treatment or prophylaxis of HCV mediated diseases with compounds of formula I and pharmaceutical compositions comprising these compounds,
Owner:RIBOSCI
Benzimidazole derivatives
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Owner:ENANTA PHARM INC
Hetero-substituted benzimidazole compounds and antiviral uses thereof
InactiveUS20040166137A1Many symptomReduce loadBiocideOrganic active ingredientsRespiratory infectionViral infection
The present invention relates to novel hetero-substituted benzimidazole compounds that have useful antiviral activity. More specifically, the invention encompasses hetero-substituted benzimidazole compounds that inhibit membrane fusion associated events such as viral transmission, reduce viral load or otherwise treat viral infections. The invention also encompasses the use of hetero-substituted benzimidazole compounds as inhibitors of membrane fusion associated events, such as viral transmission. In another embodiment, the invention encompasses processes for making hetero-substituted benzimidazole compounds, methods of using the hetero-substituted benzimidazole compounds and compositions comprising the hetero-substituted benzimidazole compounds. Finally, the invention provides methods for treating, preventing or ameliorating symptoms associated with respiratory infection, particularly that caused by Respiratory Syncytial Virus utilizing the novel benzimidazole compounds of the invention.
Owner:TRIMERIS
Hydrazide-containing hepatitis c serine protease inhibitors
The present invention relates to novel hydrazide-containing compounds of Formula I or Formula II, including pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Owner:ENANTA PHARM INC
Hepatitis c virus inhibitors
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Owner:ENANTA PHARM INC
4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
The invention provides 4-amino-4-oxobutanoyl peptide compounds of Formula Iand the pharmaceutically salts and hydrates thereof.The variables R1-R9, R16, R18, R19, n, M, n, M, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain 4-amino-4-oxobutanoyl peptide compounds disclosed herein are potent and / or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptide compounds and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain 4-amino-4-oxobutanoyl peptide compound as the only active agent or may contain a combination of 4-amino-4-oxobutanoyl peptide containing peptides compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.
Owner:ACHILLION PHARMA INC
Phosphorus-containing hepatitis C serine protease inhibitors
InactiveUS20080039375A1Inhibit serine protease activityInhibitory activityBiocideDipeptide ingredientsSerine protease activitySerine
The present invention relates to phosphorus-derived compounds of Formula I or Formula II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Owner:ENANTA PHARM INC
Melt-blown polypropylene material as well as preparation method and application thereof
ActiveCN111393754AReach killImprove filtration efficiencyDispersed particle filtrationNon-woven fabricsMasterbatchNonwoven fabric
The invention discloses a melt-blown polypropylene material as well as a preparation method and application thereof. The melt-blown polypropylene material comprises the following components: 80-99 parts of polypropylene resin; 0.5 to 10 parts of antibacterial and antiviral electret masterbatch; 0.1 to 1 part of a free radical initiator; 0.1 to 0.5 part of a nucleating agent; 0.01 to 3 parts of anantioxidant; 0-3 parts of a lubricant. According to the invention, inorganic antibacterial and antiviral particles are introduced into melt-blown polypropylene; the material is endowed with intrinsicantibacterial and antiviral characteristics; after the melt-blown non-woven fabric is prepared, when viruses and bacteria are filtered, the viruses and bacteria remain on the melt-blown layer, the nano material on the composite material can rapidly wrap the viruses and bacteria, attack the bacteria and viruses, synergistically destroy the structure of the bacteria and viruses and block electron transfer of the bacteria and viruses, so that the effects of killing the viruses and bacteria and the like are achieved, and the material has excellent antibacterial performance and antiviral performance and high filtering efficiency.
Owner:JIANGSU KINGFA SCI & TECH ADVANCED MATERIALS CO LTD +2
Antisense antiviral compound and method for treating influenza viral infection
InactiveUS20060148747A1Inhibition of replicationPromote absorptionOrganic active ingredientsBiocideInfluenzavirus CInfluenzavirus B
The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Orthomyxoviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of influenza virus infection in a mammal. The antisense antiviral compounds are substantially uncharged morpholino oligonucleotides having 1) a nuclease resistant backbone, 2) 12-40 nucleotide bases, and 3) a targeting sequence of at least 12 bases in length that hybridizes to a target region selected from the following: a) the 5′ or 3′ terminal 25 bases of the negative sense viral RNA segment of Influenzavirus A, Influenzavirus B and Influenzavirus C; b) the terminal 25 bases of the 3′ terminus of the positive sense cRNA and; and c) the 50 bases surrounding the AUG start codon of an influenza viral mRNA.
Owner:SAREPTA THERAPEUTICS INC +1
Hepatitis c virus inhibitors
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:
which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Owner:ENANTA PHARM INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Try Eureka
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap